Roivant Sciences Ltd.

Pharmaceutical Preparations

ROIVStrong5 of 9 basics passed

$35.44

+3.60%

Market cap $25.6B

$35.44

+3.60%

Market cap $25.6B

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

It is a $25.6B healthcare company. Revenue shrank 21.4% over the last year, it currently loses money, and it holds more cash than debt.

Website: roivant.com
Location: London
Employees: 721
Sector: Healthcare
Founded: 2021

Share price · 3 years

$10.70 → $35.44+231.2%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $16.9M
Loss: spends more than it earns; -$1.28B
Free cash flow: cash left after running the business; -$1.89B
Net cash: more cash than debt; $3.73B
Shares: shares outstanding; 722.7M
Volatility: beta vs the market — under 1 swings less; 1.19

Revenue, last 7 years

52-week range

Low $16.04$35.44High $41.81

Today's price is 75% of the way from the year's low to its high.

P/E vs its history6mo

1.9×median 1.9×

Higher than 27% of past days — in the cheapest third of its own history.

Valuation vs own history

P/E

1.9×

73%

P/S

3398.7×

EV/EBITDA

0.6×

73%

P/B

5.2×

22%

Share of the last ~5 years that was pricier than today (in line with its own history). Based on the daily valuation record.

Insider activity · 90 days

-$7.96Mnet selling

Purchases$0

Sales$7.96M

Insiders trading, last 14d0 buy · 2 sell

Standing in Healthcare

Size$25.6Btop 48%
Revenue growth-49%top 99%
Net margin-3535%top 99%
Return on equity-6%top 79%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong health; Valuation, Growth, Profitability, Quality and Moat lag behind.

Valuation45

P/E vs own history27th pct · 20/25
FCF yield-7.4% · 0/25
P/S3398.7x · 0/25
EV/EBITDA5.6x · 25/25

Growth0

Revenue CAGR-37.8% · 0/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growthn/a · 0/25

Profitability0

ROIC-16.0% · 0/25
ROE-6.1% · 0/25
Net margin-7594.2% · 0/25
Operating margin-7768.4% · 0/25

Health75

Altman Z40.50 · 25/25
Current ratio16.72 · 25/25
Interest coverage-72.8x · 0/25
Net cash / debtNet cash · 25/25

Quality12

Piotroski F1/9 · 0/25
Beneish M-2.11 · 12/25
FCF conversionn/a · 0/25
Margin stabilityσ 7871.2% · 0/25

Moat0

ROIC >12% yearsn/a · 0/25
Median gross marginn/a · 0/25
FCF-positive years0/7 yrs · 0/25
Worst-year net marginworst -13164.8% · 0/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

2023Acquisition
Roche completed the acquisition of Telavant from Roivant for a purchase price of $7.1 billion…
FY2023Financial
Turned profitable
$2.60B net income after a loss year
FY2023Financial
Best year on record
$2.60B net income
2022Product
Roivant and Pfizer unveiled Priovant Therapeutics
2021Founded
Priovant was established in September 2021 through a transaction between Roivant and Pfizer, in which Pfizer…
2021IPO
Roivant merged with special-purpose acquisition company Montes Archimedes Acquisition Corp
2021Acquisition
Roivant acquired Silicon Therapeutics, a small-molecule drug designer and computational physics…
2020Milestone
Roivant dosed the first patient in a clinical study evaluating gimsilumab in COVID-19 patients for…
2019Milestone
At the end of 2019, Roivant formed a $3 billion partnership with Sumitomo Dainippon Pharma and transferred its…

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$37 904 today — price return only

$1.4M revenue in FY2027

721 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (81.2%)
Net cash position after subtracting debt from cash
Altman Z-Score 40.50 — low bankruptcy-risk zone

Watch-outs

Revenue shrinking 21.4% year over year
Not profitable — 7594.2% net margin
Negative free cash flow (-$1.9B)
Thin interest coverage (-72.8×)
Loss-making in 5 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

5 of 9 checks passed

Revenue growing — the company sells more than a year ago-21.4% YoY
Profitable — makes more than it spends-$1.28B TTM
Profit growing — earnings are higher than last year+86.7% YoY
Generates cash — cash left after running and investing-$1.89B TTM
Debt under control — could handle its obligationsmore cash than debt
Established company — not a micro-cap — lower blow-up risk$25.6B market cap
Not printing shares — share count not ballooning — you keep your slice+1.4% shares over ~5y
Proven track record — years of profitability behind it1/7 profitable years
Financially stable — balance sheet not near distressAltman Z 40.5 — safe
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsno data

Peer comparisonRoivant Sciences Ltd. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
ROIV this company	$25.6B	—	-21.4%	-7594.2%	Strong
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: ROIV vs LLY · ROIV vs JNJ · ROIV vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 8Buy 9Hold 2

Appendix · Financial records

The full statements behind this CV, FY2021–FY2027. For readers who want to check the numbers.

Profit & lossRevenue $16.9M · net income -$1.28B (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2027 revenue flows to profit

RevenueNet income

Revenue (TTM)

$16.9M

YoY -21.4%

Net income (TTM)

-$1.28B

Margin -7594.2%

Gross margin

81.2%

Operating margin

-7768.4%

Income statement — full detail

Figures in USD billions · EPS in USD

	2022	2023	2024	2025	2026	2027
Revenue	0.1	0.2	0.1	0.0	0.0	0.0
Gross profit	—	—	—	—	-1.5	-0.2
Operating income (EBIT)	-3.1	2.5	-2.3	-2.3	-3.1	-0.4
Net income	-2.8	2.6	-0.2	-1.5	-1.4	-0.2
EPS (diluted)	—	3.65	-0.24	-2.11	-1.98	-0.26

Cash flowFree cash flow -$1.89B · operating cash flow -$1.88B (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

-$1.89B

Margin -11217.0%

Operating cash flow (TTM)

-$1.88B

FCF margin

-200.0%

Cash flow statement — full detail

Figures in USD billions

	2022	2023	2024	2025	2026	2027
Operating cash flow	-2.0	-2.2	-2.2	-1.9	-2.0	-0.3
Capital expenditure	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0
Free cash flow	-2.1	-2.2	-2.2	-2.0	-2.0	-0.3
FCF margin	-1886.9%	-931.1%	-1837.0%	-9835.5%	-10555.6%	-18788.0%

Balance sheetAssets $5.31B · net cash $3.73B (FY2027)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $5.31B of assets is financed

93%

Liabilities $385M — borrowed moneyEquity $4.92B — owners' stake

Cash vs debt

Total debt $107M − cash $3.84B = net cash $3.73B

Cash on hand covers all debt.

Altman Z-Score

40.50

Safe zone

Debt repayment

Not needed

Cash already covers all debt

Interest coverage

-72.8x

EBIT ÷ interest expense

ROE

-6.1%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2022	2023	2024	2025	2026	2027
Cash & equivalents	2.1	1.7	4.9	—	4.3	3.8
Total assets	2.6	2.4	5.4	—	5.7	5.3
Total liabilities	0.5	0.8	0.2	—	0.4	0.4
Total debt	0.2	0.4	—	—	0.1	0.1
Equity	1.7	1.2	4.7	—	5.3	4.9
Net debt	-1.9	-1.3	—	—	-4.2	-3.7

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of ROIV on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $35.44 · market cap $25.6B.